Dublin, Ireland, November 2, 2017
Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced that the company is scheduled to present at or attend three investor conferences in November 2017.
2017 Biotech and Money Investival Showcase
Darren Cunningham, CEO, will deliver a corporate presentation at the 2017 Biotech and Money Investival Showcase on Tuesday, November 14, at 2.30 PM. The conference takes place at Waldorf Hilton Hotel London, Aldwych, London WC2B 4DD.
Jefferies 2017 Global Healthcare Conference
Darren Cunningham will attend the Jefferies 2017 Global Healthcare Conference on Wednesday, November 15th at the Waldorf Hilton Hotel London, Aldwych, London WC2B 4DD.
Dr. Michael O’Neill, Director of Research and Development, will deliver at corporate presentation at the inaugural BioSeed® event at 11.20 AM (GMT). The event takes place at 1 More London Place, London SE1 2AF.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com